Deal Watch: Lilly Takes Global Rights To Centrexion Non-Opioid Pain Candidate
Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.
You may also be interested in...
Molteni Farmaceutici/Titan’s Sixmo, the first six-month buprenorphine implant just approved for EU marketing, could be a valued option for a sizeable number of patients.
Daiichi Sankyo denies report it is in negotiations to sell its OTC business, but might such a move actually align well with mid-term strategy?
In a deal that could be worth CHF105m, the Swiss biotech has outlicensed Raxone to Chiesi for the rare eye disease LHON as it concentrates on the drug's filing for Duchenne muscular dystrophy.